Enter NYXI with its updated Hyperion 2 Joy-Con pads, pitched as "the ultimate replacement" for the real Mc-Con. They don't ...

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final ...

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two or three is ending early due to robust positive evidence found in previous ...

In a report released on January 30, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...

Brooks Running often refreshes its markdown page but in a rare deal, the Hyperion is seeing a markdown as low as $84.

Merck (MRK) announced the Phase 3 HYPERION study evaluating WINREVAIR versus placebo in recently diagnosed adults with pulmonary arterial ...

Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension ...

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

US pharma giant Merck & Co today revealed an early stop to the Phase III HYPERION study evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently ...

In close partnership with ALLIED Feather + Down (AF+D) and premium performance wear manufacturer Active Apparel Group, Templa ...

The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.

Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...